Zobrazeno 1 - 10
of 355
pro vyhledávání: '"Sheldon H, Preskorn"'
Autor:
Sheldon H. Preskorn
Publikováno v:
Journal of Psychiatric Practice. 29:227-234
Publikováno v:
Journal of Psychiatric Practice. 29:137-141
Autor:
Sheldon H. Preskorn
Publikováno v:
Journal of Psychiatric Practice. 29:38-41
Autor:
Sheldon H, Preskorn
Publikováno v:
Journal of Psychiatric Practice. 28:130-137
This column presents a real-life case of a patient who developed severe and prolonged Parkinsonism secondary to the loading dose strategy recommended in the prescribing information (package insert) for paliperidone palmitate (Invega Sustenna). This c
Publikováno v:
Advances in Neurobiology ISBN: 9783031210532
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfb323c5d0919422e0f5d93602e4c484
https://doi.org/10.1007/978-3-031-21054-9_7
https://doi.org/10.1007/978-3-031-21054-9_7
Publikováno v:
Advances in Neurobiology ISBN: 9783031210532
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80f417d4998567e75cb74eede5e82268
https://doi.org/10.1007/978-3-031-21054-9_8
https://doi.org/10.1007/978-3-031-21054-9_8
Autor:
Sheldon H. Preskorn
Publikováno v:
Journal of Psychiatric Practice. 27:448-452
Major depressive disorder (MDD) is a descriptive, syndromic diagnosis which will likely be discovered to be more than a single disorder when understood from a pathobiological or pathoetiological perspective. To date, attempts to divide this disorder
Autor:
Sheldon H. Preskorn
Publikováno v:
Journal of psychiatric practice. 28(6)
This first column in a 2-part series focuses on the pharmacokinetics of the 3 Food and Drug Administration-approved dual orexin receptor antagonists, daridorexant, lemborexant, and suvorexant, specifically as they relate to their use as sleep medicat
Publikováno v:
Journal of Clinical Psychopharmacology. 43:87-88
Autor:
Sheldon H. Preskorn
Publikováno v:
Journal of Psychiatric Practice. 27:380-383
In response to a question posed by a valued colleague, this column will discuss 4 fundamental pharmacokinetic concepts: (1) What does the term clearance encompass? (2) What do the terms first order and second order pharmacokinetics mean? (3) What doe